Regulation of mdm2 function

• US 20040216178A1
• Filed: 03/03/2004
• Published: 10/28/2004
• Est. Priority Date: 03/03/2003
• Status: Abandoned Application

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Jones, Stephen N., Steinman, Heather
• Application Number:
  US10/793,389
• Publication Number:
  US 20040216178A1
• Time in Patent Office: Days
• US Class Current: 800/18
• CPC Class Codes: A01K 2217/075 inducing loss of function, i.e. knock out
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/03 Animal model, e.g. for test or diseases
• CPC Class Codes: A01K 67/0276 Knock-out vertebrates
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic
• CPC Class Codes: C12N 2800/30 Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
• CPC Class Codes: C12N 2830/008 cell type or tissue specific enhancer/promoter combination

Abstract

The invention provides non-human transgenic animals having conditional mdm2 transgenes integrated into their genome, cells derived therefrom, and methods for making and using both.

Claims

1. An mdm2 gene targeting vector, comprising:

(a) a first targeting sequence substantially identical to a DNA sequence 5′

of one or more exons of the mdm2 gene;

(b) a first recombinase recognition sequence;

(c) a second targeting sequence substantially identical to a DNA sequence of one or more exons of the mdm2 gene;

(d) a second recombinase recognition sequence; and

(e) a third targeting sequence substantially identical to a DNA sequence 3′

of one or more exons of the mdm2 gene.

2. The targeting vector of any claim 1, further comprising one or more selection markers.

3. The targeting vector of claim 2, wherein the selection marker is an MC1-TK negative selection marker.

4. The targeting vector of claim 2, wherein the selection marker is an antibiotic resistance gene.

5. The targeting vector of claim 2, wherein the antibiotic resistance gene is a neomycin resistance gene.

6. The targeting vector of claim 5, wherein the neomycin resistance gene is PGK-Neo.

7. The targeting vector of claim 1, wherein the targeting sequence substantially identical to a DNA sequence of one or more exons of the mdm2 gene comprises the eleventh and/or twelfth exon'"'"'s of the mdm2 gene.

8. The targeting vector of claim 1, wherein the recombinase recognition sequence is a lox sequence.

9. The targeting vector of claim 8, wherein the lox sequence is chosen from the group consisting of LoxP, Lox 66, Lox 71, Lox 511, Lox 512, and Lox 514, and variants thereof.

10. The targeting vector of claim 1, wherein the recombinase recognition sequence is a FLT sequence.

11. A method for producing a transgenic mouse comprising a conditional mdm2 allele, the method comprising:

transfecting a murine embryonic stem (ES) cell in vitro with the targeting vector of claim 1;

and

generating a transgenic mouse from the ES cell.

12. An isolated cell transfected with the targeting vector of claim 1.

13. The isolated cell of claim 12, wherein the cell is an ES cell.

14. A transgenic non-human mammal whose somatic and germ cells comprise a conditional mdm2 allele having a first recombinase recognition sequence 5′

of at least one exon of an mdm2 gene and a second recombinase recognition sequence 3′

of at least one exon of the mdm2 sequence, wherein at least some cells of the mammal exhibit decreased mdm2 expression upon exposure to a recombinase.

15. The transgenic non-human mammal of claim 14, whose somatic and germ cells comprise two conditional mdm2 alleles having a first recombinase recognition sequence 5′

of at least one exon of the mdm2 gene and a second recombinase recognition sequence 3′

of at least one exon of the mdm2 sequence, wherein the animal exhibits decreased mdm2 expression upon exposure to Cre recombinase.

16. The transgenic non-human mammal of claim 14, wherein the recombinase is a Cre recombinase or a Flp recombinase.

17. The transgenic non-human mammal of claim 14, wherein the recombinase is the Cre recombinase of bacteriophage P1 or a variant thereof.

18. The transgenic non-human mammal of claim 14, wherein the recombinase is the Flp recombinase of Saccharomyces cerevisiae.

19. An isolated cell derived from the non-human mammal of claim 14.

20. The cell of claim 19, wherein the cell is a fibroblast.

21. The cell of claim 19, wherein the cell is a mouse embryonic fibroblast (MEF).

22. A method of evaluating the effect of suppression of Mdm2 function in a mammal or a cell, organ, or tissue derived from a mammal, the method comprising:

exposing the transgenic non-human mammal of claim 14, or a cell, organ, or tissue derived therefrom, to a recombinase under conditions sufficient to cause a decrease in Mdm2 expression; and

monitoring the mammal, cell, organ, or tissue for a response;

wherein the response indicates an effect of the suppression of Mdm2 .

23. The method of claim 22, wherein the response is associated with aging.

24. The method of claim 23, wherein the response associated with aging is selected from the group consisting of hair sparseness, reduced dermal thickness, reductions in bone density, lordokyphosis, lymphoid atrophy, increased body mass, decreased lifespan, increased organ mass, retarded wound healing, and increased subcutaneous adipose levels.

25. The method of claim 22, wherein the response is wound healing.

26. The method of claim 22, wherein the response is associated with cellular transformation.

27. The method of claim 25, wherein the response associated with cellular transformation is selected from the group consisting of cellular proliferation, tumor formation, tumor growth, and metastasis.

28. The method of claim 22, wherein the recombinase is administered to the mammal by a method selected from the group consisting of tail vein injection, oral administration, and nasal administration.

29. The method of claim 22, further comprising administering a test agent to the mammal, cell, tissue or organ, and monitoring the mammal, cell, tissue or organ for a response in the presence of the test agent.